<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/60895">
      <dc:title>O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications</dc:title>
      <dc:creator>Oliver Esteve, Jaime Antonio</dc:creator>
      <dc:creator>Cabeza Montilla, Laura</dc:creator>
      <dc:creator>Perazzoli, Gloria</dc:creator>
      <dc:creator>Jiménez Luna, Cristina</dc:creator>
      <dc:creator>Doello, Kevin</dc:creator>
      <dc:creator>Ortiz Quesada, Raúl</dc:creator>
      <dc:subject>Chemoradiotherapy</dc:subject>
      <dc:subject>O6-methylguanine-DNA methyltransferase</dc:subject>
      <dc:subject>Rectal adenocarcinoma</dc:subject>
      <dc:description>Brief Report&#xd;
283</dc:description>
      <dc:description>Aims: To analyze the clinical relevance of O6-methylguanine-DNA methyltransferase in rectal adenocarcinoma treated with chemoradiotherapy followed by surgery.&#xd;
Methods: Tissue samples from 29 rectal adenocarcinoma patients were obtained after chemoradiotherapy. O6-methylguanine-DNA methyltransferase promoter methylation status was established by methylation-specific polymerase chain reaction. O6-methylguanine-DNA methyltransferase protein levels were determined by immunohistochemistry. Clinicopathologic variables, including treatment regression grade, recurrence, lymph node invasion, and stage and differentiation grade of the tumor, were determined.&#xd;
Results: The O6-methylguanine-DNA methyltransferase gene promoter was methylated in 81.5% of samples. Most patients (88.9%) showed low O6-methylguanine-DNA methyltransferase protein expression. O6-methylguanine-DNA methyltransferase methylation status was not correlated with any of the clinicopathological variables determined in rectal adenocarcinomas selected for chemoradiotherapy.&#xd;
Conclusion: O6-methylguanine-DNA methyltransferase methylation status is not correlated with clinicopathologic variables examined in rectal adenocarcinoma selected for chemoradiotherapy, although its role as a biomarker awaits further investigation.</dc:description>
      <dc:date>2020-03-31T12:22:04Z</dc:date>
      <dc:date>2020-03-31T12:22:04Z</dc:date>
      <dc:date>2019</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Oliver JA, Gómez-Millán J, Medina JA, Cabeza L, Perazzoli G, Jimenez-Luna C, et al. O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications. Balkan Med J 2019;36:283-6 [DOI: 10.4274/balkanmedj.galenos.2019.2018.12.93]</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/60895</dc:identifier>
      <dc:identifier>10.4274/balkanmedj.galenos.2019.2018.12.93</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc/3.0/es/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución-NoComercial 3.0 España</dc:rights>
      <dc:publisher>Trakya Universitesi; Galenos Publishing House</dc:publisher>
   </ow:Publication>
</rdf:RDF>